Zusammenfassung
Die Prävalenz von Epilepsien bei Personen mit Down-Syndrom (DS) ist in den zurückliegenden Jahrzehnten angestiegen, offensichtlich v. a. infolge einer Zunahme von epileptischen Anfallsleiden im höheren Patientenalter bei diesem Syndrom und parallel zu einer deutlichen Zunahme der Lebenserwartung von Menschen mit DS im Verlauf des 20. Jh.s. Die Prävalenz von Epilepsien bei Trisomie 21 liegt, alle Altersstufen zusammengenommen, nach neueren Studien bei 8–27%. Im Rahmen einer Demenz vom Alzheimer-Typ (AD) manifestieren sich beim DS Epilepsien häufig erstmalig (z. T. in mehr als zwei Drittel der Fälle) und erheblich häufiger als bei AD-Patienten, die nicht von einer Trisomie 21 betroffen sind. In diesem Zusammenhang auftretende Epilepsien sind in der Literatur mit einem sehr einheitlichen Erscheinungsbild beschrieben: Myoklonien und generalisiert tonisch-klinische Anfälle sind die im Wesentlichen beobachteten Anfallstypen, die (zumindest zeitweise) vorwiegend in der Aufwachphase registriert werden.
Abstract
The prevalence of epilepsy in Down syndrome (DS) has increased markedly over the last few decades and, according to more recent studies, is estimated to be 8–27%. When persons with DS develop Alzheimer disease (AD), more than two-thirds of the cases experience seizures for the first time. This is much more frequent than expected from non-Down syndrome patients with AD. Very similar semiology and courses of epilepsy in this situation have been described in case reports and small patient samples with myoclonic and generalized tonic-clonic seizures occurring, at least temporarily, after awakening.
Literatur
Arya R, Kabra M, Gulati S (2011) Epilepsy in children with Down syndrome. Epileptic Disord 13:1–7
Becker L, Mito T, Takashima S, Onodera K (1991) Growth and development of the brain in Down syndrome. Prog Clin Biol Res 373:133–152
Becker LE, Armstrong DL, Chan F (1986) Dendritic atrophy in children with Down’s syndrome. Ann Neurol 20:520–526
Belcastro V, Costa C, Galletti F et al (2007) Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol 14:1176–1178
Belichenko NP, Belichenko PV, Kleschevnikov AM et al (2009) The „Down syndrome critical region“ is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 29:5938–5948
Belichenko PV, Masliah E, Kleschevnikov AM et al (2004) Synaptic structural abnormalities in the Ts65Dn mouse modes of Down syndrome. J Comp Neurol 480:281–298
Bittles AH, Bower C, Hussain R, Glasson EJ (2007) The four ages of Down syndrome. Eur J Public Health 17:221–225
Buckley F, Buckley S (2008) Wrongfull deaths and rightful lives – screening for Down syndrome. Downs Syndr Res Pract 12:79–86
Collacott RA (1993) Epilepsy, dementia and adaptive behaviour in Down’s syndrome. J Intellect Disabil Res 37:153–160
Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237
Coyle JT, Oster-Granite ML, Gearhart JD (1986) The neurobiologic consequences of Down syndrome. Brain Res Bull 16:773–787
Crespel A, Gonzalez V, Coubes P, Gelisse P (2007) Senile myoclonic epilepsy of Genton: two cases in Down syndrome with dementia and late onset epilepsy. Epilepsy Res 77:165–168
Cumbo E, Ligori LD (2010) Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav 17:461–466
De Simone R, Puig XS, Gélisse P et al (2010) Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer’s disease in Down syndrome. Seizure 19:383–389
De Simone R, Daquin G, Genton P (2006) Senile myoclonic epilepsy in Down syndrome: a video and EEG presentation of two cases. Epileptic Disord 8:223–227
Dierssen M, Ramakers JA (2006) Dendritic pathology in mental retardation; from molecular genetics to neurobiology. Genes Brain Behav 5(Suppl 2):48–60
Down JL (1866) Observations on an ethic classification of idiots. Lond Hosp Clin Lect Rep 3:259–262. http://th-hoffmann.eu/archiv/down/down.1866b.pdf
Evenhuis HM (1990) The natural history of dementia in Down’s syndrome. Arch Neurol 47:263–267
Fedotov DD, Shapiro YL, Vaindrukh FA (1968) Some features of paroxysmal states in Down’s disease. Zh Neuropatol Psikhiatr Im S S Korsakova 68:1521–1527
Fernandez F, Trinidad JC, Blank M et al (2009) Normal protein composition of synapses in Ts65Dn miche: a mouse model of Down syndrome. J Neurochem 110:157–169
Ferrer I, Gulotta F (1990) Down’s syndrome and Alzheimer’s disease: dendritic spine counts in the hippocampus. Acta Neuropathol 79:680–685
Frangou S, Aylward E, Warren A et al (1997) Small planum temporal volume in Down’s syndrome: a volumetric study. Am J Psychiatry 154:1424–1429
Fujita H, Torii C, Kosaki R et al (2010) Microdeletion of the Down syndrome critical region at 21q22. Am J Med Genet A 152A:950–953
Gardiner K, Herault Y, Lott IT et al (2010) Down syndrome: from understanding the neurobiology to therapy. J Neurosci 30:14943–14945
Genton P, Paglia G (1994) Epilepsie myoclonique senile? Myoclonies épileptiques d’apparition tardive dans le syndrome de Down. Epilepsies 1:5–11
Gibbs EL, Gibbs FA, Hirsch W (1964) Rarity of 14- and 6-per-second positive spiking among mongoloids. Neurology 14:581–583
Golden JA, Bradley TH (1994) Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropathol Exp Neurol 53:513–520
Hauser WA, Morris ML, Heston LL, Anderson VE (1986) Seizures and myoclonus in patients with Alzheimer’s disease. Neurology 36:1226–1230
Hesdorffer DC, Hauser WA, Annegers JF et al (1996) Dementia and adult-onset unprovoked seizures. Neurology 46:727–730
Joensuu T, Lehesjoki A-E, Kopra O (2008) Molecular background of EPMI I – Unverricht-Lundborg disease. Epilepsia 49:557–563
Johannsen P, Christensen JE, Goldstein H et al (1996) Epilepsy in Down syndrome – prevalence in three age groups. Seizure 5:121–125
Kobayashi K, Emson PC, Mountjoy CQ et al (1990) Cerebral cortical calbindin D28 K and parvalbumin neurons in Down’s syndrome. Neurosci Lett 113:17–22
Kaufmann WE, Moser HW (2000) Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex 10:981–991
Lai F, Williams RS (1989) A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 46:849–853
Lee RK, Wurtman RJ, Cox A, Nitsch RM (1995) Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 92:8083–8087
Li LM, O’Donoghue MF, Sander JW (1995) Myoclonic epilepsy of late onset in trisomy 21. Arq Neuropsiquiatr 53:792–794
Lott IT, Head E, Doran E, Busciglio J (2006) Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 3:521–528
Lott IT, Lai F (1982) Dementia in Down’s syndrome: observations from a neurologiy clinic. Appl Res Ment Retard 3:233–239
Lozsadi DA, Larner AJ (2006) Prevalence and cause of seizures at the time of diagnosis of probable Alzheimer’s disease. Dement Geriatr Cogn Disord 22:121–124
MacGillivary RC (1967) Epilepsy in Down’s anomaly. J Ment Defic Res 17:43–48
Marin-Padilla M (1972) Structural abnormalities of the cerebral cortex in human chromosomal aberrations: a Glogi study. Brain Res 44: 625–629
McVicker RW, Shanks OE, McClelland RJ (1994) Prevalence and associated features of epilepsy in adults with Downs syndrome. Br J Psychiatry 164:528–532
Mendez MF, Catanzaro P, Doss RC et al (1994) Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol 7:230–233
Möller JC, Hamer HM, Oertel WH, Rosenow F (2001) Late-onset myoclonic epilepsy in Down’s syndrome (LOMEDS). Seizure 10:303–305
Oka A, Takashima S (1999) The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down’s syndrome brains. Acta Neuropathol 97:275–278
Pedersen B (1990) Epilepsy of late onset in Down’s syndrome: a new epileptic syndrome. Epilepsia 31:613
Pérez-Cremades D, Hernández S, Blasco-Ibáñez JM et al (2010) Alteration of inhibition of inhibitory circuits in the somatosensory cortex of Ts65n mice, a model for Down’s syndrome. J Neural Transm 117:445–455
Pinter JD, Eliez S, Schmitt JE et al (2001) Neuroanatomy of Down’s syndrome: a high-resolution MRI study. Am J Psychiatry 158:1639–1665
Prasher VP (1995) Epilepsy and associated effects on adaptive behaviour in adults with Down syndrome. Seizure 4:53–56
Prasher VP, Corbett JA (1993) Onset of seizures as a poor indicator of longevity in people with Down syndrome and dementia. Int J Geriatr Psychiatry 8:923–927
Pueschel SM, Louis S, McKnight P (1991) Seizure disorders in Down syndrome. Arch Neurol 48:318–320
Puri BK, Ho KW, Singh I (2001) Age of seizure onset in adults with Down’s syndrome. Int J Cin Pract 55:442–444
Quing H, He G, Ly PT et al (2008) Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J Exp Med 205:2781–2789
Raz N, Torres IJ, Briggs SD et al (1995) Selective neuroanatomic abnormalities in Down’s syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 45:356–366
Romano C, Tiné A, Fazio G et al (1990) Seizuers in patients with trisomy 21. Am J Med Genet Suppl 7:298–300
Ross MH, Galaburda AM, Kempre TL (1984) Down’s syndrome: is there a decreased population of neurons? Neurology 34:909–916
Sangani M, Shahid A, Amina S, Koubeissi M (2010) Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam. Epileptic Disord 12:151–154
Speller C (1994) Epilepsy in Down’s syndrome. Br J Psychiatry 165:270
Suetsugu M, Maehaein P (1980) Spine distribution along the apical dendrites of the pyramidal neurons in Down’s syndrome. A quantitative Golgi study. Acta Neuropathol 50:207–210
Takashima S, Lida K, Mito T, Arima M (1994) Dendritic and histochemical development and ageing in patients with Down’s syndrome. J Intellect Disabil Res 38:265–273
Takashima S, Ieshima A, Nakamura H, Becker LE (1989) Dendrites dementia and the Down Syndrome. Brain Dev 11:131–133
Takashima S, Becker LE, Armstrong DL, Chan F (1981) Abnormal neuronal development in the visual cortex of the human fetus and infant with Down’s syndrome. A quantitative and qualitative Golgi study. Brain Res 225:1–21
Van Allen MI, Fung J, Jurenka SB (1999) Health care concerns and guidelines for adults with Down syndrome. Am J Med Gen 89:100–110
Veall RM (1974) The prevalence of epilepsy among Mongols related to age. J Ment Defic Res 18:99–106
Vignoli A, Zambrelli E, Chiesa V et al (2011) Epilepsy in adult patients with Down syndrome: a clinical-video EEG study. Epileptic Disord 13:125–132
White NS, Alkire MT, Haier RJ (2003) A voxel-based morphometric study of nondemented adults with Down syndrome. Neuroimage 20:393–403
Wisniewski KE (1990) Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet Suppl 7:274–281
Wisniewski KE, Dalton AJ, Crapper McLachlan DR et al (1985) Alzheimer’s disease in Down’s syndrome: clinicopathologic studies. Neurology 35:957–961
Zigman WB, Lott I (2007) Alzheimer’s disease in Down syndrome: neurobiology and risk. Ment Retard Dev Diabil Res Rev 13:237–246
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martin, P. Trisomie 21, Demenz vom Alzheimer-Typ und Epilepsie. Z. Epileptol. 25, 41–48 (2012). https://doi.org/10.1007/s10309-011-0212-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10309-011-0212-8